¿Qué aporta prosigna en el tratamiento adyuvante de pacientes con cáncer de mama? - page 13

(J Clin Oncol 2016)

HR+/HER-neg and NODE-negative

INDICATION Evidence Quality

Recomendation Strenght

PAM 50 ROR

YES

HIGH

STRONG

HR+/HER-neg and NODE-positive

INDICATION Evidence Quality

Recomendation Strenght

PAM 50 ROR

INTERMEDIATE

MODERATE

SEO Version

Warning.

You are currently viewing the SEO version of !text.
It has a number of design and functionality limitations.

We recommend viewing the Flash version or the basic HTML version of this publication.

1...,3,4,5,6,7,8,9,10,11,12 14,15,16,17,18,19,20,21,22,23,...24